Novo Nordisk Science

For US Healthcare Professionals

This site provides U.S. healthcare professionals with scientific information on unapproved uses of approved or cleared medical products. All information is intended to be non-promotional in nature, scientifically sound, and shared in line with FDA guidance. Please consult full prescribing information before making any clinical practice decisions for the care and management of individual patients. 

The presentations below were developed by Novo Nordisk Inc. and must be viewed with the provided source publication that is the subject of the corresponding presentation.

Wegovy® tablet / Ozempic® tablet

Website

Disclosures and Firm-Generated Presentation

Website

Source Publication: Efficacy and safety of once-daily oral semaglutide 25mg and 50mg compared with 14mg in adults with type 2 diabetes

Website

Wegovy® Prescribing Information

Website

Ozempic® tablet Prescribing Information

Wegovy® injection

Website

Disclosures and Firm-Generated Presentation

Website

Source Publication: Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

Website

Wegovy® Prescribing Information

NovoSeven® RT

Website

Disclosures

Website

The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia

Website

NovoSeven® RT Prescribing Information

Continue
Continue